Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Qiu (Princeton, NJ, United States of America), R. Zhao (Princeton, NJ, United States of America), B. Elpers (Princeton, NJ, United States of America), Y. Wang (Ann Arbor, MI, United States of America), L. Xie (Ann Arbor, MI, United States of America), J. Tang (Ann Arbor, MI, United States of America), A. Fischer (Princeton, NJ, United States of America). Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. 1851

Member's Comments

No comment yet.

Related content which might interest you: Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Impact of depression on patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 The Effects Of Respiratory Viruses on The Acute Pulmonary Exacerbations In Cystic Fibrosis Patients Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Risk Factors for Mortality in Patients with Idiopathic Pulmonary Fibrosis Followed at Intensive Care Unit due to Acute Respiratory Failure Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 Predictors of Progression in Patients with Pulmonary Sarcoidosis Source: Virtual Congress 2020 – Clinical issues in granulomatous lung diseases Year: 2020 Histopathologic and Molecular Analysis of Idiopathic Pulmonary Fibrosis Lungs from Patients Treated with Pirfenidone or Nintedanib Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Idiopathic Pulmonary Haemosiderosis; Factors That Effect Prognosis Source: Virtual Congress 2020 – Tip the hat to paediatric bronchology Year: 2020 Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis Source: International Congress 2019 – Bronchiectasis Year: 2019